Benha Journal of Applied Sciences (BJAS) **print: ISSN 2356–9751**
Vol. (9) Issue (12) (2024), (31- 37) **online: ISSN 2356–976x**
http://bjas.bu.edu.eg
Medical and Health Science

Psoraisis. Background Pathophysiology, Clinical Manifestation and Treatment

Hasnaa M.Elesawy, Fatma M.Elesawy, Samah E.Ibrahim and Asmaa A.Elfallah
Dermatology, Venerology and Andrology Department, Faculty of Medicine, Benha University
E-mail : h.elesawy1987@gmail.com

Abstract
Objectives: The This page is structured to provide a comprehensive overview of Psoriasis , including its causes, symptoms, and treatment options. Setting the Scene: Between two and three percent of the world's population suffers with Psoriasis , a persis tent autoimmune dis order. Characteris tic characteris tics of psoriatic patients include angiogenesis , immunological dysfunction, and epidermal hyperproliferation. Various processes have been proposed to be involved in the pathogenesis of Psoriasis , however the exact process remains unknown. Data Sources: Studies that examined the pathogenesis , clinical presentation, and the rapy of Psoriasis up to the year 2024 were located via a search and study of the Medline databases [Pub Med and Medscape]. Research Prioritis ation: The inclusion of all research was determined by separate evaluations. Inclusion was contingent upon the m meeting the following requirements: 1. The language of writing and publication is Englis h. 2. Featured in journals that undergo a rigorous peer review process.3. Go over the causes, symptoms, and treatments of Psoriasis again. Data Extraction: Studies were omitted from consideration if the y faIL ed to meet the inclusion criteria. Ethical permis sion, clear eligibIL ity criteria, suitable controls, sufficient information, and well-defined evaluation measures were all variables in determining the study's quality. We used a data collecting form to independently extract information relevant to our research results from all qualifying studies. In summary: Skin inflammation manifests as Psoriasis . More and more treatment options have emerged as a result of advances in our knowledge of Psoriasis 's pathophysiology, which has the potential to greatly enhance the quality of life for those living with the condition.

Keywords : Psorais is , pathophysiology, clinical manifestation, and treatment are the main terms.

Introduction

Psoriasis is an inflammatory skin condition that often affects the extensor regions of the body, such as the elbows, knees, scalp, and chest. The plaques, which are red and coated in white scales, may be itchy at times and are most often seen on the se places [1]. Prevalence and incidence vary greatly by region, age group, and sex, making it one of the most frequent chronic skin dis orders. [2] The IL lness's pathogenesis is not fully understood, although several variables, including genetics, environmental factors [such as cigarette smoke and air pollution], stress, and othe rs, are believed to have a role in the development and progression of the dis ease. Treatments for Psoriasis may be eithe r systemic or applied topically. As part of the treatment plan, we aim to achieve PASI improvements of at least 75% [PASI75] or 90% [PASI90], which corresponds to absolute PASI scores of no more than 4 or 2, respectively. [4]

Review of literature:

Skin condition; Psoriasis

Psoriasis affects several ethnic groups with varied frequencies; it is a chronic skin IL lness that is mediated by the immune system. About 85–90% of all Psoriasis cases occur on the skin, and plaque Psoriasis is by far the most prevalent kind. [5] Although it differs between locations, the global frequency is about 2%. Asian and some African ethnicities have a lower incidence, whereas Caucasian and Scandinavian cultures might have a prevalence of up to 11%. the sixth

Psoriasis incidence peaked between the ages of 30 and 39 and again between the ages of 60 and 69, revealing a bimodal age trend in the start of the dis ease. Based on the establis hed criteria, chronic plaque Psoriasis may be categoris ed as eithe r 'type I' [early onset] or 'type II' [late onset], with the former being described as appearing at age 40 or beyond and the latter as occurring at age < 40. [7]

Possible causes:

Psoriasis is a multifaceted IL lness that has several potential causes, including genetics, the immune system, and environmental variables. Uncontrolled proliferation of keratinocytes and defective differentiation are hallmarks of Psoriasis , which is characteris ed by chronic inflammation. Psoriasis has a hereditary compone nt, as shown by patterns of famIL y aggregation [see point 8]. Psoriasis is more common among first- and second-degree relatives of those who have the condition, and the ris k is two to three times higher in monozygotic twins than in dizygotic one s. the ninth

Pustular Psoriasis , as well as clinical syndromes exhibiting just a subset of pustular Psoriasis symptoms, may be caused by variations in one of six genes. A severe autoinflammatory syndrome of the skin and bone s can manifest with widespread pustules and bone inflammation when a mutation occurs in the IL -1RA gene [IL 1RN], which encodes for several proteins including IL 36RN, CARD14, AP1S3, TNIP1, SERPINA3, and TNIP3. in ten

Immunopathogenesis : Inflammation, antigen presentation, cell signalling, and transcriptional control are some of the mechanis ms that might set off Psoriasis , a complicated hereditary condition. Uncontrolled proliferation of keratinocytes and defective differentiation are hallmarks of Psoriasis , which is characteris ed by chronic inflammation. [11] Skin KIL ler Cells and Keratinocytes:

The re are many different kinds of cells that make up the skin, making it the biggest organ in the body. Dendritic cells [DCs], macrophages, and neutrophIL s are examples of innate immune cells; B and T cells are examples of adaptive immune cells; and keratinocytes, melanocytes, and endothe lial cells are examples of resident skin cells. This interplay is very dynamic in Psoriasis . Chronic inflammation seems to be amplified and maintained by the se interactions. [12]

Through the release of cytokines [such as IL -6, IL -1γ, and TNF-α] and chemokines [such as CCL20, CXCL5, CXCL8, CXCL9, and CXCL10], keratinocytes maintain the inflammatory environment. [13]

Psoriasis is characteris ed by the overabundance of neutrophIL s in psoriatic lesions. In the skin, keratinocytes and dendritic cells primarIL y release IL -36, which leads to the accumulation of neutrophIL granules. IL -36 is expressed in three different variants, all of which are members of the IL -1 famIL y: IL -36α, β, and γ. Once IL -36 binds to its receptor IL -36Rα, it activates NF kappa B, which in turn increases the transcription of several inflammatory mediators. [14] Interactions between IL -36 and othe r inflammatory cytokines, such as IL -17, furthe r amplify inflammation. Excessive neutrophIL accumulation at inflammatory sites and uncontrolled inflammation are both caused by mutations or polymorphis ms in genes that regulate IL -36. Curiously, people who did not get relief from standard treatments may get a great deal of relief with neutrophIL depletion [15].

Influential in antimicrobial defence and maintaining a balance between pro- and anti-inflammatory substances, innate lymphoid cells [IL Cs] are a relatively new area of study within the innate immune system. The se cells do not have antigen-specific receptors. The capacity to create IL -22 and IL -17A suggests that among the three kinds, IL C3 plays the most significant role in Psoriasis . The levels of IL C3 in the blood and skin of patients with the dis ease are higher than those in healthy people [16].

T cells: The process of recognis ing antigens given by APCs in the skin involves a highly organis ed mechanis m known as T cell signalling. Important interactions between dermal DCs and T cells [CD8+, Th1, autoreactive T cells, Th17, and Th22] play a role in the development of Psoriasis [17]. Dermal DCs stimulate Th1, Th17, and Th22 responses using the cytokines IL -12 and IL -23. As a result of the ir changes to epidermal differentiation and stimulation of hyperproliferation, the se helper T cells reduce apoptosis in the skin [18].

Protecting specific areas of the body from environmental threats is an important function of tis sue resident T cells [TRM]. Tis sue-reactive molecules [TRMs] trigger cytotoxic, inflammatory, and antibacterial reactions. Active and resolved psoriatic lesions have an increased concentration of IL -17 and IL -22 generating TRM, which influences the development and maintenance of a psoriatic plaque [19].

- **Immunoglobulin classes:**

IL -1: IL Macrophages, monocytes, and othe r cell types generate several members of the -1 famIL y, including IL -α and IL -β. When the se peptides bind to the IL -1 receptor type 1 [IL -1R] and its accessory protein [IL -1RAcP], it sets in motion a cascade of events inside the cell that include intracellular signalling molecules including MyD88 and IRAKs. Finally, inflammatory immunological responses are caused by the stimulation of transcription factors like NFκB. [20]. IL -1β is recognis ed as having a crucial function in Psoriasis . SimIL ar to a mouse model of Psoriasis generated by imiquimod, elevated mRNA levels have been seen in lesional skin compared to healthy skin. In Psoriasis , it promotes inflammation by increasing IL -17 production and inducing T cell proliferation [21].

Although IL -23 cannot activate naïve T cells on the ir own due to the lack of matching receptors on the se cells, it plays a crucial role in regulating the Th17-driven pathogenesis of Psoriasis . Through the transcription

factor RORγt, which may be activated by IL -23 to generate proinflammatory cytokines like IL -17 and TNFα, IL -6, IL -1, and TGFβ facIL itate the transformation of CD4 cells into Th17 cells. Human psoriatic skin has an overexpression of IL -23, and wIL d-type mice may develop lesions simIL ar to Psoriasis when injected with this protein. The development of anti-IL -23 mAbs, which proved to be very effective in treating Psoriasis , was driven by its critical involvement in the molecular pathogenesis of the dis ease [22].

Autoimmunity has been shown for several dis orders, including Psoriasis , inflammatory bowel dis ease, rheumatoid arthritis , and IL -17, due to its proinflammatory effects on the immune system. Hepatic steatosis and arteriosclerosis are metabolic dis eases linked to lifestyle choices, and IL -17 plays a role in the inflammatory processes that accompany the se conditions. In addition to alleviating Psoriasis , IL -17 antagonis ts may help with othe r common health problems [23].

The expression of interleukin-22 [IL -22] is upregulated in psoriatic lesional skin, and serum IL -22 levels are correlated with dis ease activity. The thickness and scaling of the epidermis are caused by IL -22, which stimulates keratinocyte migration and inhibits the ir differentiation. Furthe rmore, it promotes neutrophIL invasion and inflammation by inducing the release of chemokines and antimicrobial peptides. This led researchers to speculate that IL -22 may be a the rapeutic target for Psoriasis . However, IL -22 inhibitor phase I studies were halted because the y were ineffective [24].

The Th1 responses and the induction of IFN -γ are significantly impacted by IL -12. We predicted IL -22 to play a pivotal role in Psoriasis pathogenesis as well, since IL -12 enhances IFN -γ and TNF-α. Neverthe less, the re was no dis cernible increase in IL -12 p35 subunit expression in psoriatic skin. It has recently been dis covered that the p40 subunit may be effectively targeted to treat Psoriasis by inhibiting IL -23[25].

A. The microbiome:

The The psoriatic plaque has a greater variety of microbes. Gao et al. [2008] dis covered that psoriatic plaques had an increase in the phyla Firmicutes and Actinobacteria. The re were more proteobacteria in healthy skin samples than in psoriatic skin samples. Psoriatic lesion trunk skin biopsies did, however, reveal an increase in Proteobacteria. WhIL e one research indicated that Staphylococci were much lower in psoriatic skin compared to healthy controls, anothe r indicated that Corynebacterium, Propionibacterium, Staphylococcus, and Streptococcus were all elevated in psoriatic skin [26].

Clinical Presentation: The afflicted region of the body determines the clinical form of Psoriasis , which may vary in appearance [27].

The presence of chronic plaque:

Classic Psoriasis , the most common and immediately identifiable form of the dis ease, is characteris ed by the presence of clearly defined plaques, which are salmon-pink in colour and coated in sIL very scales on white skin and grey on black skin. Small bleeding spots, called the Auspitz sign, may occur when adhering scales are removed. Although it may include any part of the skin, the most common places for it to happen are on the external sides of the knees and elbows, in the lumbosacral region, and on the scalp [rarely spreading beyond the hairline] [28].

Othe r forms of Psoriasis include:

Intestinal Psoriasis

As a centripetal dis tribution of several tiny scaly papules, guttate Psoriasis accounts for 2% of all cases. Roughly 50% of patients have high streptozyme, anti-DNase B, or antis treptolysin O titres, and 65% have a his tory of pharyngitis or tonsIL litis [29].

2. Psoriasis with erythroderma

Though it occurs more often as a consequence of flaring IL lness, erythroderma is a severe and sometimes fatal variant of Psoriasis that affects around 2-3% of individuals with the dis order. More than 75% of the body's surface area may be covered with scales or exhibit exfoliation when this condition is present [30].

3.Multiple pustules on the skin

Generalized The autoinflammatory IL lness known as pustular Psoriasis is characteris ed by life-threatening flares, sterIL e pustules, and pyrexia. It affects more women than males and differs epidemiologically from chronic plaque Psoriasis . Some factors that might cause generalis ed pustular Psoriasis include infection, hypocalcaemia, pregnancy, and the quick reduction of systemic and powerful topical corticosteroids [31].

Palmoplantar pustulosis is a case of

Traditional symptoms of palmoplantar pustulosis include the development of purulent, yellow pustules on the soles and palms, which, after a few weeks, turn into macules of reddis h brown colour. Most cases of palmoplantar pustulosis are in middle-aged women [between the ages of 30 and 60] who smoke [current or former smokers]; about 20% of the se patients also have chronic plaque Psoriasis [32].

The chronic acrodermatitis of Hallopeau

Pustules on the tips of fingers and sometimes toes are the hallmark of the uncommon IL lness known as acrodermatitis continua of Hallopeau, which may cause the naIL plate to fall off. About 40% of those with this condition also suffer with chronic plaque Psoriasis [33].

6.SeboPsoriasis

In addition to the scalp, seborrhoeic facial areas [such as the nasolabial folds and eyebrows] and postauricular and parasternal regions may also be affected by seboPsoriasis . As far as taxonomy is concerned, seborrhoeic dermatitis , dandruff, and seboPsoriasis are all up for dis cussion. number 34.

Psoriasis of the naIL s

In approximately half of cases of plaque Psoriasis , the condition can also manifest on the naIL s. This can take many forms, including tiny pits on one or all twenty naIL plates, separation of the naIL plate from the naIL bed [onycholysis], oIL spots [orange-yellow dis colouration of the naIL bed], or crumbling [dystrophy] of the naIL plates. Psoriatic arthritis is twice as likely and the IL lness lasts twice as long in individuals with naIL dis ease, especially onycholysis , compared to those with Psoriasis who do not have naIL dis ease [35].

Medical The rapy

The re Psoriasis may be effectively treated with a variety of alternatives, including as systemic medication, targeted photothe rapy, calcineurin inhibitors, keratolytics, Vitamin D analogues, and topical corticosteroids. that is , 36.

Vitamin D analogues [calcipotriol] and corticosteroids are examples of topical treatments that are considered first line of defence. [37] One manner in which topical corticosteroids function is by lowering inflammatory pathways, which in turn reduces inflammation, inhibits cell proliferation, and constricts blood vessels [38]. Vitamin D analogues applied topically promote keratinocyte differentiation whIL e suppressing the ir proliferation.The number 39.

Conventional systemic medications such as methotrexate, ciclosporin, and acitretin, as well as photothe rapy using narrowband ultraviolet B radiation [NB-UVB] and psoralen with ultraviolet A radiation [PUVA], make up second-line the rapy. The hazards of skin cancer associated with cumulative dosages of PUVA have led to NB-UVB's essentially replacing PUVA[40].

Methotrexate blocks lymphocytes by aDENOSINE accumulation, aminoimidazole carboxamide ribotide transformase [AICARTase] blockage, and dihydrofolate reductase inhibition, among othe r ways. One major side effect is that it suppresses the bone marrow. The recommended dosage of methotrexate is once weekly adminis tered orally. The increased absorption and less gastrointestinal adverse effects of subcutaneous formulation make it the superior choice [41].

The re is a ris k of hypertension and permanent kidney damage associated with ciploxin, a calcineurin inhibitor, despite its fast start of action. As an oral retinoid, acitretin promotes the development of keratinocytes. Dry skin, thinning hair, hyperlipidaemia, and liver damage are some of the potential adverse effects. It is not recommended to use methotrexate or acitretin when pregnant [42].

To combat proinflammatory cytokines, biologics use monoclonal antibodies or soluble receptors. The ir influence on outcomes in moderate-severe IL lness has been substantial. For moderate to severe Psoriasis , the re are a number of approved biological the rapies, including inhibitors of tumour necrosis factor [TNF] [adalimumab, etanercept, infliximab, and certolizumab], interleukin-12/23p40 [ustekinumab], interleukin-23p19 [rizankizumab, guselkumab, and tIL drakizumab], interleukin-17 [ixekizumab and secukinumab], and IL -17 receptor [brodalumab]. Each patient requires a personalis ed approach when selecting a biologic, since the re is no universally accepted "best" agent. the number 43.

References

[1] A., Rendon, & K. Schäkel. Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, vol,20[6], pp:1475. 2019

[2] AW, Armstrong MD, Mehta CW, Schupp GC, Gondo SJ, Bell CE Griffiths. Psoriasis prevalence in adults in the United States. JAMA dermatology. Aug vol,1;157[8]:pp:940-6. 2021.

[3] MV, Medovic VL, Jakovljevic VI, Zivkovic NS, Jeremic JN, Jeremic SB, Bolevich AB, Ravic Nikolic VM, MIL icic IM Srejovic. Psoriasis between autoimmunity and oxidative stress: changes induced by different the rapeutic approaches. Oxidative medicine and cellular longevity. 2022;2022[1]:2249834.

[4] SK, MahIL N, WIL N, son Dand NJ, Reynolds CE, Griffiths R, Emsley A, Marsden I, Evans RB, Warren D, Stocken JN Barker. Psoriasis treat to

target: defining outcomes in Psoriasis using data from a real-world, population-based cohort study [the Britis h Association of Dermatologis ts Biologics and Immunomodulators Regis ter, BADBIR]. Britis h Journal of Dermatology. 2020 May vol,1;182[5]:vol:1158-66.

[5] i, R., Paris Is I. Y. K., kandar, E., Kontopantelis , M., Augustin, C. E. M., Griffiths, D. M., Ashcroft, & G. P. Atlas, National, regional, and worldwide epidemiology of Psoriasis : systematic analysis and modelling study. BMJ [Clinical Research Ed.], vol, 369, pp:m1590–m1590. 2020.

[6] S, AlQassimi S, AlBrashdi H, Galadari MJ Hashim. Global burden of Psoriasis –comparis on of regional and global epidemiology, 1990 to 2017. International Journal of Dermatology. 2020 May;vol,59[5]:pp:566-71.

[7] IY, Is kandar R, Paris i CE, Griffiths DM, Ashcroft Global Psoriasis Atlas. Systematic review examining changes over time and variation in the incidence and prevalence of Psoriasis by age and gender. Britis h Journal of Dermatology. 2021 Feb vol,1;184[2]:pp:243-58.

[8] B., Nedoszytko, A., Szczerkowska-Dobosz, M., Stawczyk-Macieja, k, A., Owczarczyk-Saczone A., Reich, J., Bartosiñska, A., Batycka-Baran, R., Czajkowski, I. T., Dobrucki, & L. W. Dobrucki. Pathogenesis of Psoriasis in the "omic" era. Part II. Genetic, genomic and epigenetic changes in Psoriasis . Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol,37[3], pp:283. 2020.

[9] A., Szczerkowska-Dobosz, D., Krasowska, J., Bartosińska, M., Stawczyk-Macieja, A., Walczak, k, A., Owczarczyk-Saczone A., Reich, A., Batycka-Baran, Czajkowski, R., & Dobrucki, I. T. Pathogenesis of Psoriasis in the "omic" era. Part IV. Epidemiology, genetics, immunopathogenesis , clinical manifestation and treatment of psoriatic arthritis . Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol,37[5], pp:625. 2020.

[10] R, Uppala LC, Tsoi PW, Harms B, Wang AC, BIL li E, Maverakis Michelle J, Kahlenberg NL, Ward JE. Gudjonsson "Autoinflammatory Psoriasis "—genetics and biology of pustular Psoriasis . Cellular & molecular immunology. 2021 Feb;vol,18[2]:pp:307-17.

[11] F., Grän, A., Kerstan, E., Serfling, M., Goebeler, & K. Muhammad. Focus: Skin: Current Developments in the Immunology of Psoriasis . The Yale Journal of Biology and Medicine, vol,93[1], pp:97. 2020.

[12] S. E., Vidal Yucha, K. A., Tamamoto, & D. L. Kaplan, The importance of the neuro-immuno-cutaneous system on human skin equivalent design. Cell Proliferation, vol,52[6], pp:e12677. 2019.

[13] T., Rauschenberger, V., Schmitt, M., Azeem, S., Klein-Hessling, K., Murti, F., Grän, M., Goebeler, A., Kerstan, M., Klein, & T. Bopp. T cells control chemokine secretion by keratinocytes. Frontiers in Immunology, 1917. 2019.

[14] C.-C., Chiang, W.-J., Cheng, M., Korinek, C.-Y., Lin, & T.-L. Hwang, NeutrophIL s in Psoriasis . Frontiers in Immunology, 2376. 2019.

[15] M. P. Schön, Adaptive and innate immunity in Psoriasis and othe r inflammatory dis orders. Frontiers in Immunology, vol,10, pp:1764. 2019.

[16] J. M., Murphy, L., Ngai, A., Mortha, & S. Q. Crome. Tis sue-dependent adaptations and functions of innate lymphoid cells. Frontiers in Immunology, vol,13, pp:836999. 2022.

[17] A, Shahi S, Afzali A, Amirzargar P, Mohaghegh S, Salehi Y Mansoori. Potential roles of inflammasomes in the pathophysiology of Psoriasis : A comprehensive review. Molecular Immunology. 2023 Sep vol, 1;161:pp;44-60.

[18] A, Raharja SK, MahIL JN Barker. Psoriasis : a brief overview. Clinical Medicine. 2021 May vol,1;21[3]:pp:170-3.

[19] C, Dong L, Lin J Du. Characteris tics and sources of tis sue-resident memory T cells in Psoriasis relapse. Current Research in Immunology. 2023 Jan vol,1;4:pp:100067.

[20] **P., Galozzi, S., Bindoli, A., Doria, & o, P Sfris.** The revis ited role of interleukin-1 alpha and beta in autoimmune and inflammatory dis orders and in comorbidities. Autoimmunity Reviews, vol,20[4], pp:102785. 2021.

[21] Y., Cai, F., Xue, C., Quan, M., Qu, N., Liu, Y., Zhang, C., Fleming, X., Hu, H., Zhang, & R Weichselbaum,. A critical role of the IL -1β–IL -1R signaling

pathway in skin inflammation and Psoriasis pathogenesis . Journal of Investigative Dermatology, vol,139[1], pp:146–156. 2019.

[22] A, Campanati A, Marani E, Martina F, Diotallevi G, Radi A Offidani. Psoriasis as an Immune-Mediated and Inflammatory Systemic Dis ease: From Pathophysiology to Novel The rapeutic Approaches. *Biomedicines*. 2021; vol,9[11]:pp:1511.

[23] K. H. G. MIL ls, IL -17 and IL -17-producing cells in protection versus pathology. Nature Reviews Immunology, vol,23[1], pp:38–54. 2023.

[24] B, Wang D, Han F, Li W, Hou L, Wang L, Meng K, Mou S, Lu W, Zhu Y Zhou. Elevated IL -22 in Psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL/Bax. Apoptosis . 2020 Oct;vol,25[9]:pp:663-73.

[25] P, Zwicky F, Ingelfinger SIL va de Melo BM, Ruchti F, Schärli S, Puertas N, Lutz M, Phan TS, Kündig TM, Levesque MP, Maul JT. IL -12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Science immunology. 2021 Oct vol,22;pp:6[64]:eabg9012.

[26] SM WIL chowski. The role of the gut microbiome in Psoriasis : from pathogens to pathology. The Journal of clinical and aesthe tic dermatology. 2022 Mar;15[3 Suppl 1]:S25.

[27] S. R., Feldman, & K. C. Duffin. Psoriasis : epidemiology, clinical manifestations, and diagnosis . UpToDate. Waltham, MA: UpToDate Inc. Retrieved from: Https://Www. Uptodate. Com Accessed, vol,5. 2019.

[28] CE, Griffiths AW, Armstrong JE, Gudjonsson JN Barker. Psoriasis . The Lancet. 2021 Apr vol, 3;397[10281]:pp:1301-15.

[29] AK, Leung B, Barankin JM, Lam KF Leong. ChIL dhood guttate Psoriasis : An updated review. Drugs in context. 2023;vol,12.

[30] OY, CarrasquIL lo G, Pabón-Cartagena LA, Falto-Aizpurua M, Santiago-Vázquez KJ, Cancel-Artau G, Arias-Berrios RF Martín-García. Treatment of erythrodermic Psoriasis with biologics: a systematic review. Journal of the American Academy of Dermatology. 2020 Jul vol,1;83[1]:pp:151-8.

[31] MJ, Gooderham AS, Van Voorhees MG Lebwohl. An update on generalized pustular Psoriasis . Expert review of clinical immunology. 2019 Sep vol,2;15[9]:pp:907-19.

[32] E, Freitas MA, Rodrigues T Torres. Diagnosis , screening and treatment of patients with palmoplantar pustulosis [PPP]: a review of current practices and recommendations. Clinical, Cosmetic and Investigational Dermatology. 2020 Aug vol,14:pp:561-78.

[33] C, Kromer E, Loewe ML, Schaarschmidt A, Pinter S, Gerdes D, Celis S, Poortinga WIL D, smann-The is R Mössner. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients. The Journal of dermatology. 2020 Sep;vol,47[9]:pp:989-97.

[34] JN, Cohen S, Bowman ZG, Laszik JP North. Clinicopathologic overlap of Psoriasis , eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis , seboPsoriasis , and tumor necrosis factor α inhibitor–associated dermatitis . Journal of the American Academy of Dermatology. 2020 Feb vol,1;82[2]:pp:430-9.

[35] C, Ji H, Wang C, Bao L, Zhang S, Ruan J, Zhang T, Gong B Cheng. Challenge of naIL Psoriasis : an update review. Clinical Reviews in Allergy & Immunology. 2021 Dec vol,1:pp:1-26.

[36] C.A.; Elmets, N.J.; Korman, E.F.; Prater, E.B.; Wong, R.N.; Rupani, D.; Kivelevitch, A.W.; Armstrong, C.; Connor, K.M.; Cordoro, D.M.R.; Davis , et al. Joint AAD-NPF Guidelines of care for the management and treatment of Psoriasis with topical the rapy and alternative medicine modalities for Psoriasis severity measures. *J. Am. Acad. Dermatol.* **2021**, vol,*84*,pp: 432–470.

[37] J.T.; Maul, F.; Anzengruber, C.; Conrad, A.; Cozzio, P.; Häusermann, i, A.; JalIL A.G.A.; Kolios, E.; Laffitte, A.K.; Lapointe, C.; Mainetti, et al. Topical Treatment of Psoriasis Vulgaris : The Swis s Treatment Pathway. *Dermatology* **2021**, vol, *237*, pp:166–178.

[38] J.T.; Maul, F.; Anzengruber, C.; Conrad, A.; Cozzio, P.; Häusermann, i, A.; JalIL A.G.A.; Kolios, E.; Laffitte, A.K.; Lapointe, C.; Mainetti, et al. Topical Treatment of Psoriasis

Vulgaris : The Swis s Treatment Pathway. *Dermatology* **2021**, vol, *237*, pp:166–178

[39] D, Amiri CW, Schwarz L, Gethe r SK Lone . Safety and efficacy of topical calcineurin inhibitors in the treatment of facial and genital Psoriasis : a systematic review. Acta Dermato-Venereologica. 2023;vol,103.

[40] H-J, Lee M Kim. Challenges and Future Trends in the Treatment of Psoriasis . *International Journal of Molecular Sciences*. 2023; vol,24[17]:pp:13313

[41] AM, van Huizen R, Sikkel AG, Caron SP, Menting PI Spuls. Methotrexate dosing regimen for plaque-type Psoriasis : an update of a systematic review. Journal of Dermatological Treatment. 2022 Nov vol,17;33[8]:pp:3104-18.

[42] S, Pandey P, Tripathi A, Gupta JS Yadav. A comprehensive review on possibIL ities of treating Psoriasis using dermal cyclosporine. Drug Delivery and Translational Research. 2022 Jul vol,1:pp:1-5.

[43] ND, Brownstone J, Hong M, Mosca E, Hadeler W, Liao T, Bhutani J Koo. Biologic treatments of Psoriasis : an update for the clinician. Biologics: Targets and The rapy. 2021 Feb vol,16:pp:39-51.